Thursday, May 31, 2012

BRIEF-Bristol Myers CEO says Gilead/Bristol hepatitis C drugs should be tested together

May 31 (Reuters) - Bristol-Myers Squibb Co :

* CEO says company will not "downsize" research and development, but adjust it in accordance with ongoing performance of company

* CEO says biggest mid-term company focus will be on oncology, virology, anti-coagulation

* CEO says Gilead and Bristol should combine their respective experimental medicines for hepatitis c in late-stage trials

* CEO says he suspects Gilead would prefer instead to first explore combinations of gilead's own hepatitis c medicines

* CEO says expects some form of subsequent healthcare reform even if supreme court shoots down health care law

* CEO says U.S. healthcare reform started on right foot, but then became too complicated for drugmakers and American people

* CEO says significant future company sales growth will come from Asia, not from Europe

((New York Equities Desk; tel: +1 646 223 6000))

((For more news about Bristol-Myers Squibb Co click here: ))

(C) Reuters 2012. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters.

No comments:

Post a Comment